Inactive Instrument
GOLD SWAP Share Price OTC Bulletin Board
Stocks
GDSW
US38074W1009
Biotechnology & Medical Research
|
End-of-day quote
OTC Bulletin Board
|
||
| - USD | - |
|
| 18/09 | Silo Pharma Receives U.S. Patent Allowance For SPC-15 Ptsd Treatment | CI |
| 09/09 | Silo Pharma Highlights Patented Nose-To-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum | CI |
| Market Cap | 27.79L 24.43L 23.01L 21.03L 39.31L 27Cr 39.65L 2.76Cr 1.07Cr 14Cr 1.04Cr 1.02Cr 44Cr | P/E 2024 |
-0.75x | P/E 2025 | -0.67x |
|---|---|---|---|---|---|
| Enterprise Value | -40.79L -35.86L -33.77L -30.87L -57.69L -39Cr -58.19L -4.04Cr -1.57Cr -20Cr -1.53Cr -1.5Cr -65Cr | EV / Sales 2024 |
-42.8x | EV / Sales 2025 | -32.3x |
| Free-Float |
88.28% | Yield 2024 * |
-
| Yield 2025 | - |
| 19/24/19 | Top Midday Decliners | MT |
| 28/23/28 | Laidlaw Initiates Silo Pharma With Buy Rating, Price Target is $10 | MT |
| Manager | Title | Age | Since |
|---|---|---|---|
Eric Weisblum
CEO | Chief Executive Officer | 57 | 27/11/2015 |
Daniel Ryweck
DFI | Director of Finance/CFO | 61 | 27/09/2022 |
James Kuo
CTO | Chief Tech/Sci/R&D Officer | 60 | 01/09/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Eric Weisblum
CHM | Chairman | 57 | 27/11/2015 |
Wayne Linsley
BRD | Director/Board Member | 69 | 16/01/2020 |
Kevin Muñoz
BRD | Director/Board Member | 47 | 01/10/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.46% | +5.87% | +5.75% | +33.71% | 4.76TCr | |
| +2.67% | +2.31% | +47.50% | +38.37% | 4.41TCr | |
| -1.38% | +3.42% | +9.39% | +88.88% | 4.15TCr | |
| +4.78% | +2.01% | +352.12% | +566.20% | 4.09TCr | |
| -0.62% | +0.11% | +1.12% | +46.02% | 2.97TCr | |
| +0.56% | +0.67% | +25.08% | +155.71% | 1.72TCr | |
| +2.05% | +4.04% | +24.47% | +41.67% | 1.51TCr | |
| +3.39% | -6.86% | - | - | 1.47TCr | |
| +7.38% | +17.54% | -2.25% | - | 1.38TCr | |
| Average | +1.01% | +0.69% | +57.90% | +138.65% | 2.94TCr | |
| Weighted average by Cap. | +0.95% | +0.96% | +71.88% | +147.49% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 72.1T 63.38T 59.69T 54.56T 1L 69.18L 1L 7L 3L 35.24L 3L 3L 1.14Cr | 72.1T 63.38T 59.69T 54.56T 1L 69.18L 1L 7L 3L 35.24L 3L 3L 1.14Cr |
| Net income | -43.93L -38.61L -36.37L -33.24L -62.12L -42Cr -62.67L -4.35Cr -1.69Cr -21Cr -1.65Cr -1.61Cr -70Cr | -42.28L -37.16L -35L -31.99L -59.79L -41Cr -60.31L -4.19Cr -1.63Cr -21Cr -1.59Cr -1.55Cr -67Cr |
| Net Debt | -70.81L -62.24L -58.62L -53.58L -1Cr -68Cr -1.01Cr -7.02Cr -2.72Cr -35Cr -2.66Cr -2.6Cr -112.43Cr | -68.59L -60.29L -56.78L -51.9L -96.99L -66Cr -97.84L -6.8Cr -2.64Cr -34Cr -2.58Cr -2.52Cr -108.91Cr |
Employees
-
- Stock Market
- Stocks
- SILO Stock
- GDSW Stock
Select your edition
All financial news and data tailored to specific country editions
